GlycoMimetics, Inc. Stock price
Is GlycoMimetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.
Key metrics
GlycoMimetics, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a GlycoMimetics, Inc. forecast:
Analyst Opinions
7 Analysts have issued a GlycoMimetics, Inc. forecast:
Don't miss a Thing! We will send you all news about GlycoMimetics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
| Head office | United States |
| CEO | Harout Semerjian |
| Employees | 4 |
| Founded | 2003 |
| Website | glycomimetics.com |


